The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agenus; Amgen; Bristol-Myers Squibb; Janssen-Cilag; MacroGenics; MSD; Pfizer; Roche; Ryvu Therapeutics
Consulting or Advisory Role - Roche
Research Funding - Agenus
Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors.
 
Rafal Dziadziunszko
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Foundation Medicine; Karyopharm Therapeutics; MSD; Novartis; Pfizer; Regeneron; Roche
Research Funding - Ryvu Therapeutics
 
Elena Garralda
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Janssen; MAB Discovery; NeoMed; Roche; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Ribon Therapeutics (Inst); Roche (Inst); Seagen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)
 
Noemi Angelosanto
Employment - Ryvu Therapeutics
Stock and Other Ownership Interests - Ryvu Therapeutics
 
Tomasz Rzymski
Employment - Ryvu Therapeutics
Stock and Other Ownership Interests - Ryvu Therapeutics
 
Renata Dudziak
Employment - Ryvu Therapeutics
 
Krzysztof Brzózka
Employment - Ryvu Therapeutics
Stock and Other Ownership Interests - Ryvu Therapeutics
 
Peter Littlewood
Employment - Ryvu Therapeutics
Stock and Other Ownership Interests - Ryvu Therapeutics
 
Hendrik Nogai
Employment - Bayer; Ryvu Therapeutics
Leadership - Bayer; Ryvu Therapeutics
Stock and Other Ownership Interests - Bayer
 
Axel G. Glasmacher
Leadership - Ryvu Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Ryvu Therapeutics
 
Iwona Lugowska
No Relationships to Disclose